TRDA 10-Q: SEC filing
Entrada Therapeutics
Filed with the SEC on · accession 0001689375-26-000064
TRDA filed a 10-Q (quarterly report) with the SEC on Nov 5, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved -10.1% by the first close after the filing.
Summary of the filing
Entrada Therapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, confirming its status as an accelerated filer and reporting 39,150,334 shares of common stock outstanding.
Key details
How TRDA stock reacted
Close before
$5.06
Nov 4, 2026
First close after
-10.08%
$4.55
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for TRDA, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for TRDA?
Click hereFrequently asked questions
What did TRDA file with the SEC on Nov 5, 2026?
TRDA filed a 10-Q (SEC filing). Entrada Therapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, confirming its status as an accelerated filer and reporting 39,150,334 shares of common stock outstanding.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did TRDA stock react to this filing?
TRDA closed at $5.06 before the filing and $4.55 on Nov 5, 2026 (-10.08%).
Other TRDA SEC filings
Get alerts when TRDA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days